17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020 Download PDF Post navigationPreviousPrevious post:Corrective press release regarding adverse events information from study AB09004NextNext post:Masitinib in Alzheimer’s Disease Webcast PresentationRelated PostsBoursorama interview of Alain Moussy, CEO of AB ScienceDecember 23, 2020Capital raise for a total amount of 15 million eurosDecember 21, 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseDecember 18, 2020Masitinib in Alzheimer’s Disease Webcast PresentationDecember 17, 2020Corrective press release regarding adverse events information from study AB09004December 17, 2020Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s DiseaseDecember 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s DiseaseDecember 16, 2020
